Pepticom is pleased to announce that Pierre Riviere, PhD has joined the companys Scientific Advisory Board to advise Pepticom on its peptide therapeutics strategy, programs and business. Dr. Riviere has over 25 years of biopharmaceutical industry experience with R&D leadership roles in target and drug discovery, nonclinical and early-stage clinical development. He is a recognized expert in peptide therapeutics with both established peptide modalities and emerging novel peptide technologies. Dr. Riviere is Founder and CEO of Peptide Logic, a San Diego-based biotech company developing novel peptide therapeutic modalities. He previously was CSO at CovX, a leading peptide-antibody conjugates company, a SVP of Pfizer worldwide R&D and member of the Pfizer Leadership Team, and before, SVP Research at Ferring Pharmaceuticals, a leading peptide therapeutics company. He is also a co-founder of Cara Therapeutics and of the Peptide Therapeutics Foundation and the Annual Peptide Therapeutics Symposium. Dr. Riviere received a PhD in animal physiology and biology from the Institut National Polytechnique, Toulouse, and completed postdoctoral studies at the University of Arizona, Tucson.
Pepticom's CEO, Dr. immanuel lerner speaks at a panel in the 2018 China Langfang international Conference on Economy and Trade"
Save the date, come and meet Pepticom's at the Bio 2018 conference in Boston, MA. For more information: firstname.lastname@example.org
Dr. Maayan Elias Robicsek , Pepticom's BDO, will attend the Israel BIOMED conference in Tel aviv. We will be happy to see you there! For more information, please contact: email@example.com
Come and meet our team at the Start-Up Space in the Agrivest 2018 conference! For more information please contact: firstname.lastname@example.org
Come and meet us at the AI conference in Berlin, Germany on June 19th-20th. Dr. Amit Michaeli, Pepticom CTO will discuss principles from our algorithm: From Finance to AI Drug Discovery. For more information: email@example.com
Dr. immanuel lerner, Pepticom's CEO, is an invited speaker at the BASEL LIFE Peptide Therapeutic Forum in September 13-14 2018. We will be happy to meet during the conference. For more information: firstname.lastname@example.org
Pepticom's new article From finance to molecular modeling algorithms: The risk and return heuristic" describe a novel new approach for Peptide discovery. http://www.researchtrends.net/tia/title_issue.asp?id=26&in=0&vn=18&type=3"
Pepticom's BDO, Dr. Maayan Elias Robicsek will attend the BIO-EUROPE SPRING 2018 partnering conference on March 12-14 in Amsterdam, The Netherlands. For more information:email@example.com
Pepticom has signed a third collaboration agreement with ADAMA Agricultural Solutions in the field of crop protection.
9/10/17 Pepticom initiates beta-testing for cyclotide discovery algorithm. If you have a protein target and want to find a cyclotide that binds it please contact: firstname.lastname@example.org
Dr. Amit Michaeli, Pepticom's CTO, is invited speaker at the BASEL LIFE Peptide Therapeutic Forum on September 12-13 2017. For more information: email@example.com
Pepticom's CEO attended and presented the company and the technology in the Shenzhen International Bio-Valley event.
Pepticom will attend the PEPTIDES conference in London, on July 6-7. For more information:firstname.lastname@example.org
Pepticom's CTO, Amit Michaeli, will give a talk about Artificial intelligence designed TLR4 peptide activators" on September 12 at the Peptide Therapeutics Forum 2017 (part of Basel life 2017). "
Pepticom congratulates Prof. Amiram Goldblum, founder and director, for winning the prestigious 2017 Kaye Innovation awards for dramatic improvements in drug discovery methods.
Pepticom will attend the 3rd INNOVATION China-Israel investment summit in China. For more information and schedule: email@example.com
Pepticom's CEO, Dr.immanuel lerner will attend the 2017 BIO International Convention, June 19-22 in San Diego, California. For more information:firstname.lastname@example.org
Pepticom is honored to join the Israeli delegation to SelectUSA 2017, bringing our unique technology together with American minds to create leading products in the 21st century. Come and meet us: email@example.com
Pepticom was selected as one of the 500 most promising tech startups to participate in the Pioneers Festival 2017 at the Hofburg Imperial Palace in Vienna. Come and meet us on June 1st &2nd. For more information please contact: firstname.lastname@example.org
Meet us at the Israeli BioMed 2017! May 25th at booth 8 in the startup pavilion area. For more info contact: email@example.com
Pepticom and Hadasit Medical Research and Services Ltd., the technology transfer company of Hadassah University Hospitals, on behalf of Prof. Dina Ben Yehuda, Head of the department of Hematology, signed a collaboration agreement for the development of novel anti-cancer molecules
The EUREKA project, DENOSYNTRAC, performed with Fraunhofer institute and EMC microcollection in Germany, was successfully completed with the discovery of a large library of Immuno-active peptides
Invited speaker to the Connex-Yissum event in Jerusalem
Pepticom attended the 2016 EuroPEPTIDE conference (part of TIDES) in Berlin, Germany
Pepticom increases technology capacity to small-molecule discovery
Pepticom attended the 2016 BioSpain conference in Bilbao, Spain as part of the official Israeli delegation
Pepticom would like to thank US president Barack Obama, Secretary of State John Kerry, Ambassador Shapiro and the great staff at the US Embassy for an excellent SelectUSA2016 summit!
BIOCEV director prof. Paul Mart?sek visits Pepticom to discuss future collaborations
Invited speakers at JBNF pitch event
Pepticom's technology was successfully implemented in the discovery of a stabilizing peptide for glycogen branching enzyme (GBE) in collaboration with Oxford university and Hadassah medical center. See article "Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design" (human molecular genetics July 2015)
Invited speakers at VLX summer event "Rebuilding Traditional Business Models in Healthcare".
Pepticom has entered into a collaboration with ADAMA Agricultural Solutions Ltd. (formerly Makhteshim Agan Industries Ltd.).
Invited speakers at the best of both event in Leipzig
Pepticom initiated research geared at small molecule discovery, based on the exclusive pharmacophore of its binding peptides.
Dozens of new peptide modulators discovered and validated in innate immunity, Alzheimerís and cancer projects.
Invited speakers in BioMed Israel innovation conference.
Pepticom announces a collaboration with Professor Alan S. Kopin at Tufts Medical Center in Boston to develop opioid receptor modulators.
Pepticom announces collaboration with Fraunhofer institute to develop innate immunity modulators.
EUREKA label approved for Pepticom in joint collaboration with EMC Microcollections and Stuttgart University (IGVP, Stuttgart), to develop Toll-like receptors modulators.
EUREKA label approved for pepticom and TargetEx on development of new anti-Alzheimerís disease drugs by designing BACE1 and AChE binding peptides.
New pending patent issued by pepticom in the field of innate immunity.
Pepticom offices move to a new location: Malha Technology Park (GATI), Building 8, 3rd floor, Jerusalem, Israel.
Pepticom initiates multiple projects in the fields of neurology, cancer and cardiovascular diseases.
Pepticom undergoes seed investment.